| Title |
Overcoming the Blood-Brain Barrier in Chemotherapy Treatment of Pediatric Brain Tumors
|
|---|---|
| Published in |
Pharmaceutical Research, August 2013
|
| DOI | 10.1007/s11095-013-1196-z |
| Pubmed ID | |
| Authors |
Linfeng Wu, Xiaoxun Li, Dileep R. Janagam, Tao L. Lowe |
| Abstract |
Pediatric brain tumors are most common cancers in childhood and among the leading causes of death in children. Chemotherapy has been used as adjuvant (i.e. after) or neoadjuvant (i.e. before) therapy to surgery and radiotherapy for the management of pediatric brain tumors for more than four decades and gained more attention in the recent two decades. Although chemotherapy has demonstrated its effectiveness in the management of some pediatric brain tumors, failure or inactiveness of chemotherapy is commonly met in the clinics and clinical trials. Some of these failures might be attributed to the blood-brain barrier (BBB), limiting the penetration of systemically administered chemotherapeutics into pediatric brain tumors. Therefore, various strategies have been developed and used to address this issue. Herein, we review different methods reported in the literature to circumvent the BBB for enhancing the present of chemotherapeutics in the brain to treat pediatric brain tumors. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 2% |
| France | 1 | 2% |
| Unknown | 48 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 6 | 12% |
| Researcher | 5 | 10% |
| Other | 4 | 8% |
| Student > Postgraduate | 4 | 8% |
| Student > Master | 4 | 8% |
| Other | 10 | 20% |
| Unknown | 17 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 16% |
| Agricultural and Biological Sciences | 6 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 8% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Unspecified | 2 | 4% |
| Other | 11 | 22% |
| Unknown | 17 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 March 2014.
All research outputs
#14,647,929
of 22,745,803 outputs
Outputs from Pharmaceutical Research
#2,185
of 2,854 outputs
Outputs of similar age
#117,844
of 200,119 outputs
Outputs of similar age from Pharmaceutical Research
#23
of 33 outputs
Altmetric has tracked 22,745,803 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,854 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.0. This one is in the 23rd percentile – i.e., 23% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 200,119 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 33 others from the same source and published within six weeks on either side of this one. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.